Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial
White, Harvey D, Steg, Ph Gabriel, Szarek, Michael, Bhatt, Deepak L, Bittner, Vera A, Diaz, Rafael, Edelberg, Jay M, Erglis, Andrejs, Goodman, Shaun G, Hanotin, Corinne, Harrington, Robert A, Jukema, J Wouter, Lopes, Renato D, Mahaffey, Kenneth W, Moryusef, Angele, Pordy, Robert, Roe, Matthew T, Sritara, Piyamitr, Tricoci, Pierluigi, Zeiher, Andreas M, Schwartz, Gregory G
Published in European heart journal (01.09.2019)
Published in European heart journal (01.09.2019)
Get full text
Journal Article
Safety and efficacy of evinacumab, a monoclonal antibody to ANGPTL3, in patients with homozygous familial hypercholesterolemia: A single-arm, open-label, proof-of-concept study
Gaudet, D, Gipe, D.A, Khoury, É, Pordy, R, Sasiela, W, Chan, K.C
Published in Atherosclerosis (01.09.2016)
Published in Atherosclerosis (01.09.2016)
Get full text
Journal Article
Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in four phase 3 odyssey trials with/without statin background
Robinson, J.G, Farnier, M, Kastelein, J.J, Roth, E.M, Taskinen, M.R, Colhoun, H.M, Brunet, A, DiCioccio, A.T, Lecorps, G, Pordy, R, Baccara-Dinet, M.T, Cannon, C.P
Published in Atherosclerosis (01.09.2016)
Published in Atherosclerosis (01.09.2016)
Get full text
Journal Article
Relationship between alirocumab, PCSK9 and LDL-C levels: results from the odyssey mono phase 3 trial of alirocumab 75 mg every 2 weeks
Farnier, M, Kastelein, J.J.P, Roth, E, Taskinen, M.R, Ginsberg, H.N, Colhoun, H.M, Robinson, J.G, Merlet, L, Brunet, A, Pordy, R, Baccara-Dinet, M.T
Published in Atherosclerosis (01.08.2014)
Published in Atherosclerosis (01.08.2014)
Get full text
Journal Article
ONE YEAR OPEN-LABEL TREATMENT WITH ALIROCUMAB 150 MG EVERY TWO WEEKS IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIC PATIENTS
Dufour, R, Stein, E.A, Bergeron, J, Gaudet, D, Weiss, R, Du, Y, Yang, F, Andisik, M, Torri, A, Pordy, R, Gipe, D.A
Published in Canadian journal of cardiology (01.10.2014)
Published in Canadian journal of cardiology (01.10.2014)
Get full text
Journal Article
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, Gregory G, Steg, P. Gabriel, Szarek, Michael, Bhatt, Deepak L, Bittner, Vera A, Diaz, Rafael, Edelberg, Jay M, Goodman, Shaun G, Hanotin, Corinne, Harrington, Robert A, Jukema, J. Wouter, Lecorps, Guillaume, Mahaffey, Kenneth W, Moryusef, Angèle, Pordy, Robert, Quintero, Kirby, Roe, Matthew T, Sasiela, William J, Tamby, Jean-François, Tricoci, Pierluigi, White, Harvey D, Zeiher, Andreas M
Published in The New England journal of medicine (29.11.2018)
Published in The New England journal of medicine (29.11.2018)
Get full text
Journal Article
Evinacumab reduces remnant cholesterol in patients with hypercholesterolemia or hypertriglyceridemia
Rosenson, R.S., Rader, D., Ali, S., Banerjee, P., Mcginniss, J., Pordy, R.
Published in Atherosclerosis (01.08.2022)
Published in Atherosclerosis (01.08.2022)
Get full text
Journal Article
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
Bittner, Vera A., Szarek, Michael, Aylward, Philip E., Bhatt, Deepak L., Diaz, Rafael, Edelberg, Jay M., Fras, Zlatko, Goodman, Shaun G., Halvorsen, Sigrun, Hanotin, Corinne, Harrington, Robert A., Jukema, J. Wouter, Loizeau, Virginie, Moriarty, Patrick M., Moryusef, Angèle, Pordy, Robert, Roe, Matthew T., Sinnaeve, Peter, Tsimikas, Sotirios, Vogel, Robert, White, Harvey D., Zahger, Doron, Zeiher, Andreas M., Steg, Ph. Gabriel, Schwartz, Gregory G.
Published in Journal of the American College of Cardiology (21.01.2020)
Published in Journal of the American College of Cardiology (21.01.2020)
Get full text
Journal Article
Evinacumab reduces EU apheresis eligibility in patients with homozygous familial hypercholesterolemia
Raal, F., Rosenson, R., Moriarty, P., Ali, S., Banerjee, P., Zhao, J., George, R.T., Mcginniss, J., Pordy, R.
Published in Atherosclerosis (01.08.2023)
Published in Atherosclerosis (01.08.2023)
Get full text
Journal Article
Safety, tolerability and pharmacokinetics of evinacumab, an angiopoietin-like protein 3 (ANGPTL3) inhibitor, in healthy Japanese and Caucasian subjects
Harada-Shiba, M., Ali, S., Gipe, D.A., Gasparino, E., Son, V., Pordy, R., Catapano, A.L.
Published in Atherosclerosis (01.12.2020)
Published in Atherosclerosis (01.12.2020)
Get full text
Journal Article
Lipoprotein(a) and the effect of alirocumab on coronary and non-coronary revascularization following acute coronary syndrome
Steg, P, Szarek, M, Valgimigli, M, Islam, S, Zeiher, A M, Bhatt, D L, Bittner, V A, Diaz, R, Goodman, S G, Harrington, R A, Jukema, J W, Pordy, R, Scemama, M, White, H D, Schwartz, G G
Published in European heart journal (03.10.2022)
Published in European heart journal (03.10.2022)
Get full text
Journal Article
Evinacumab markedly reduces low-density lipoprotein cholesterol in adolescent patients with homozygous familial hypercholesterolemia
Reeskamp, L.F., Greber-Platzer, S., Saheb, S., Stefanutti, C., Stroes, E.S.G., Ali, S., Banerjee, P., Pordy, R., Zhao, J., Raal, F.J.
Published in Atherosclerosis (01.08.2021)
Published in Atherosclerosis (01.08.2021)
Get full text
Journal Article
A phase 2 trial of the efficacy and safety of evinacumab in patients with severe hypertriglyceridemia
Rosenson, R.S., Gaudet, D., Ballantyne, C.M., Baum, S.J., Bergeron, J., Kershaw, E.E., Moriarty, P.M., Rubba, P., Banerjee, P., Ponda, M.P., Pordy, R., Son, V., Rader, D.J.
Published in Atherosclerosis (01.08.2021)
Published in Atherosclerosis (01.08.2021)
Get full text
Journal Article
The efficacy and safety of evinacumab in homozygous familial hypercholesterolaemia (HoFH) patients with little to no low-density lipoprotein receptor (LDLR) activity
Raal, F.J., Rosenson, R.S., Reeskamp, L.F., Kastelein, J.J., Baum, S., Ali, S., Banerjee, P., Chan, K.-C., Gipe, D.A., Pordy, R., Gaudet, D.
Published in Atherosclerosis (01.12.2020)
Published in Atherosclerosis (01.12.2020)
Get full text
Journal Article
Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery
Goodman, Shaun G., Aylward, Philip E., Szarek, Michael, Chumburidze, Vakhtang, Bhatt, Deepak L., Bittner, Vera A., Diaz, Rafael, Edelberg, Jay M., Hanotin, Corinne, Harrington, Robert A., Jukema, J. Wouter, Kedev, Sasko, Letierce, Alexia, Moryusef, Angele, Pordy, Robert, Ramos López, Gabriel Arturo, Roe, Matthew T., Viigimaa, Margus, White, Harvey D., Zeiher, Andreas M., Steg, Ph. Gabriel, Schwartz, Gregory G.
Published in Journal of the American College of Cardiology (03.09.2019)
Published in Journal of the American College of Cardiology (03.09.2019)
Get full text
Journal Article
Effect of alirocumab on incidence of atrial fibrillation after acute coronary syndromes: insights from ODYSSEY OUTCOMES
Lopes, R, Steg, P.G, Bhatt, D.L, Bittner, V.A, Dauchy, A, Diaz, R, Goodman, S.G, Harrington, R.A, Jukema, J.W, Pordy, R, Sourdille, T, Szarek, M, White, H.D, Zeiher, A.M, Schwartz, G.G
Published in European heart journal (01.11.2020)
Published in European heart journal (01.11.2020)
Get full text
Journal Article
4115Effect of alirocumab on recurrent cardiovascular events after acute coronary syndrome, according to the intensity of background statin treatment
Diaz, R, Li, Q H, Bhatt, D L, Bittner, V A, Baccara-Dinet, M T, Goodman, S G, Jukema, J W, Parkhomenko, A, Pordy, R, Reiner, Z, Szarek, M, Tse, H F, Zeiher, A M, Schwartz, G G, Steg, P G
Published in European heart journal (01.10.2019)
Published in European heart journal (01.10.2019)
Get full text
Journal Article
P1226Very low achieved low-density lipoprotein cholesterol level with alirocumab treatment after acute coronary syndrome: ODYSSEY OUTCOMES
Schwartz, G, Szarek, M, Li, Q H, Chiang, C E, Diaz, R, Hagstrom, E, Huo, Y, Jukema, J W, Lecorps, G, Moryusef, A, Pordy, R, White, H D, Yusoff, K, Zeiher, A M, Steg, P G
Published in European heart journal (01.10.2019)
Published in European heart journal (01.10.2019)
Get full text
Journal Article